**NM signifies a non meaningful value. A dash signifies the data is not available.

Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now ...

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying ...

Developed under the direction and sponsorship of Gilead Sciences, Inc. At the AIDS 2024 congress ... the clinic and in the health systems to fight the HIV epidemic. Watch a summary of the symposium ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

In Type 1 diabetes (T1D), insulin-producing β-cells are killed by islet-infiltrating immune cells in a process called “insulitis”. T1D results in a critical requirement for exogenous insulin and ...

Details The technical summary data tells us to buy GILD near 77.18 ... Updated AI-Generated Signals for Gilead Sciences Inc. (GILD) available here: GILD.

1 Investigators hypothesized that a side-by-side descriptive summary of efficacy with the approaches will ... Bristol Myers ...